Catalent Logo
US1488061029
A112H2
CTLT

Catalent

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 67,33 € (+12,35 %). Medianen er 57,59 € (-3,90 %).

Køb
  8
Behold
  12
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Lisata Therapeutics licenses Certepetid to Catalent for SMARTag-ADC platform

    Lisata Therapeutics has entered a global, non-exclusive license agreement with Catalent granting Catalent rights to use the cyclic iRGD peptide Certepetid for antibody–drug conjugates within the SMARTag-ADC platform. Catalent will cover research, development and commercialization costs; Lisata will receive milestone payments of up to $10.5 million as well as tiered revenue participation and shares of sublicense payments. Catalent may terminate the agreement with 30 days' notice; Lisata retains a right of first negotiation in out-licensing processes. Additionally, Lisata reported Q2 results with better-than-expected EPS performance, about $22 million in cash and a buy recommendation from H.C. Wainwright with a $15.00 price target. » Mere på de.investing.com


  • Catalent secures global rights to Lisata's Certepetide for ADC development

    Catalent has obtained worldwide, non-exclusive rights to evaluate Certepetide and its analogs as payloads in antibody–drug conjugates and can integrate the peptide into its SMARTag ADC platform. The agreement permits collaborations with third parties and includes staged milestone payments of more than $10 million plus revenue participation for Lisata. Preclinical data on integrating iRGD peptides into SMARTag ADCs will be presented in November at the World ADC Conference. Certepetide holds Fast Track and orphan drug status for certain indications, supporting its clinical relevance. » Mere på de.investing.com


  • Regeneron expects FDA decision on higher-dose Eylea in fourth quarter

    An inspection at manufacturer Catalent initially delayed the U.S. approval process for a higher-dose Eylea. Novo Nordisk (after acquiring Catalent) provided comprehensive responses to the FDA in early August 2025, according to Regeneron. Regeneron expects the production issues to be resolved quickly and for the FDA to rule on the applications in the fourth quarter, which gave the stock a strong boost and also lifted Scholar Rock. Analysts view the earlier timing of the decision as positive for Regeneron. » Mere på deraktionaer.de


  • Precigen closes supply agreement with Catalent for commercial manufacture of PAPIZEMOS

    Precigen has entered a three-year commercial supply agreement with Catalent Maryland, Inc. for the exclusive external fill-finish and final manufacturing of PAPIZEMOS. At the same time, PAPIZEMOS received full FDA approval as the first approved therapy for recurrent respiratory papillomatosis in adults, prompting analysts to raise price targets. The contract includes minimum purchase commitments, annual pricing provisions and automatic renewal clauses. » Mere på de.investing.com


  • Silexion implements reverse split to secure NASDAQ listing

    Silexion announces a 1-for-15 reverse split to meet NASDAQ's minimum price requirements and maintain its listing. The biotechnology company is facing significant financial challenges but reports progress in the development of its RNA interference therapies and a new partnership with Catalent. At the annual general meeting, shareholders approved key measures, including the election of the board of directors and the appointment of Kesselman & Kesselman as auditors. » Mere på de.investing.com

Virksomhedstal

I det seneste år havde Catalent en omsætning på 4,08 mia. € og et nettoresultat på -971,59 mio. €
(EUR) 2024
YoY
Omsætning 4,08 mia. 4,19 %
Bruttofortjeneste 887,75 mio. 8,58 %
Nettoresultat -971,59 mio. 357,17 %
EBITDA -264,55 mio. 208,57 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
10,45 mia. €
Antal aktier
181,51 mio.
Højeste/laveste i 52 uger
57,59 € - 38,19 €
Udbytte Nej
Beta
1,16
P/E (PE Ratio)
-11,02
PEG (PEG Ratio)
-0,32
K/I (PB Ratio)
3,19
P/S (PS Ratio)
2,63

Virksomhedsprofil

Catalent, Inc. udvikler og fremstiller sammen med sine datterselskaber løsninger til lægemidler, proteinbaserede biologiske lægemidler, celle- og genterapier samt forbrugersundhedsprodukter på verdensplan. Virksomheden er organiseret i fire segmenter: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery og Clinical Supply Services. Segmentet Softgel and Oral Technologies leverer formulering, udvikling og fremstilling af bløde kapsler til brug i en række kundeprodukter, såsom receptpligtige lægemidler, håndkøbsmedicin, kosttilskud, enkeltdosisprodukter til kosmetik og veterinærmedicinske præparater. Segmentet Biologics leverer biologiske cellelinjer; udvikler og fremstiller celleterapi og virusbaseret genterapi; formulering, udvikling og fremstilling af parenterale doseringsformer, herunder hætteglas, fyldte sprøjter, hætteglas og patroner; samt analytisk udvikling og testydelser. Segmentet Oral and Specialty Delivery tilbyder formulering, udvikling og fremstilling på tværs af en række teknologier sammen med integrerede downstream-løsninger til klinisk udvikling og kommerciel forsyning. Segmentet tilbyder desuden en platform for orale leveringsløsninger, der omfatter prækliniske screeninger, formulering, analytisk udvikling og ydelser inden for current good manufacturing practices. Segmentet Clinical Supply Services tilbyder fremstilling, emballering, opbevaring, distribution og lagerstyring af lægemidler og biologiske lægemidler til kliniske forsøg. Det tilbyder også FastChain, efterspørgselsdrevne kliniske forsyningsydelser. Virksomheden betjener farmaceutiske virksomheder, bioteknologiske virksomheder og forbrugersundhedsvirksomheder samt virksomheder inden for andre sundhedsmarkeder, såsom dyresundhed og medicinsk udstyr, samt inden for kosmetikbranchen. Catalent, Inc. blev stiftet i 2007 og har hovedkontor i Somerset, New Jersey.

Navn
Catalent
CEO
Alessandro Maselli
Hjemsted Somerset, nj
USA
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
31.07.2014
Medarbejdere 17.000

Tickersymboler

Børs Symbol
NYSE
CTLT
Frankfurt
0C8.F
SIX
0C8.SW
München
0C8.MU
🍪

Parqet  bruger cookies. Læs mere